Drugs / rC19
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06695117 | Nov 2024 → Apr 2026 | — | Sanofi | Completed | No outcome recorded |
| Phase 1/2 | NCT06695130 | Nov 2024 → Apr 2026 | — | Sanofi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rC19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06695117 ↗ |
| Modality | Vaccine | “rC19 (adjuvanted recombinant COVID-19 vaccine)” NCT06695117 ↗ |
| Route | Intramuscular | “administered via a single intramuscular (IM) injection” NCT06695130 ↗ |